Sanofi (NYSE:SNY) filed a patent infringement suit against Mylan (NSDQ:MYL) yesterday in the U.S. District Court of New Jersey, alleging that the EpiPen-maker infringed upon 18 patents covering Sanofi’s Lantus insulin glargine injection and SoloStar pen. The suit was triggered by a notice from Mylan in mid-September, Sanofi said. Mylan told the insulin-maker that it had […]
Sanofi-Aventis
Sanofi invests $200m to expand France-based vaccine production facility
Sanofi (NYSE:SNY) plans to spend more than $200 million to expand a vaccine manufacturing site in Val de Reuil, France. The company said that the new facility will allow its global vaccines biz to expand its supply of VaxigripTetra, a quadrivalent flu vaccine, to up to 70 countries in six continents. “Influenza continues to be a major […]
Sanofi, Innovation Health to evaluate digital health solutions for Type II diabetes
Innovation Health and Sanofi (NYSE:SNY) said today that the companies are launching a pilot program to evaluate the impact of digital health solutions from One Drop and Common Sensing for people with Type II diabetes. The program hopes to enable pharmaceutical companies, tech companies and plan providers to work together to improve patient outcomes, according to […]
Study: 30% of T2D patients don’t start insulin therapy when recommended
Research from Brigham & Women’s Hospital, supported by Sanofi (NYSE:SNY), found that 30% of people with Type II diabetes don’t begin insulin therapy when it’s first recommended to them. On average, these patients are delaying treatment by two years, the researchers reported. The team’s work was published in the journal of Diabetic Medicine. “Unfortunately this isn’t uncommon, […]
Sanofi touts patient-driven dose titration of Toujeo insulin glargine injection
Sanofi (NYSE:SNY) today touted data from the Take Control trial of its Toujeo insulin glargine product in patients with Type II diabetes. The study compared patients using Toujeo with a titration algorithm managed by the patient, compared to patients whose dose adjustment was decided by their physicians. The 631-patient trial revealed that after six months, patients […]
Sanofi’s Toujeo beats Lantus at stabilizing blood sugar in T2D patients
Adults with Type II diabetes treated with Sanofi‘s (NYSE:SNY) Toujeo Gla-300 insulin glargine had better blood glucose stability than those treated with the company’s Lantus Gla-100 insulin glargine product, according to a study presented at the annual meeting of the European Association for the Study of Diabetes. The analysis re-analyzed patient data from the Edition […]
Study: Sanofi’s diabetes drug brings earlier blood sugar control than insulin glargine
A post-hoc analysis of two late-stage trials of Sanofi‘s (NYSE:SNY) Soliqua insulin glargine and lixisenatide injection showed that it provides blood sugar control earlier and in more adults than just insulin glargine, the company reported. The analysis was presented today at the European Association for the Study of Diabetes in Portugal. Researchers reviewed data from […]
Regeneron, Sanofi tout topline Ph3 data for injectable asthma drug
Sanofi (NYSE:SNY) and Regeneron (NSDQ:REGN) touted data today from the pivotal Phase III trial of dupilumab in a group of patients with uncontrolled, persistent asthma. The drug is already approved for adults with certain forms of eczema. The two companies said they plan to seek FDA approval of dupilumab in asthma by the end of the year. […]
Enteris BioPharma launches endometriosis trial with oral peptide delivery tech
Enteris BioPharma, a 24-person biotech based in Boonton, N.J., last month launched a trial of its oral leuprolide endometriosis therapy, Ovarest. Ovarest is the company’s most advanced internal candidate and represents Enteris’ attempt to overcome the challenges presented by the oral delivery of peptides, according to CEO Joel Tune. The Phase IIa trial, which is […]
Sanofi wins tentative FDA nod for Admelog insulin lispro injection
Sanofi (NYSE:SNY) said today that the FDA granted the company tentative approval for its Admelog insulin lispro injection. The decision is based on physicochemical, non-clinical and clinical similarity to another, already-approved insulin lispro injection. The compound is contraindicated during hypoglycemia episodes and in patients with hypersensitivity to insulin lispro or one of its other ingredients, […]